89226-75-5 Usage
Description
Manidipine hydrochloride is a dihydropyridine calcium channel blocker with high selectivity for vasculature, exhibiting antihypertensive properties. It is a clinically useful antihypertensive agent and has been found to inhibit the SARS-CoV-2 main protease, 3CLpro, as well as act as an early entry inhibitor of human cytomegalovirus by inhibiting the Immediate-Early 2 (IE2) protein.
Uses
Used in Pharmaceutical Industry:
Manidipine hydrochloride is used as an aldosterone antagonist for the treatment of hypertension. It helps in lowering blood pressure by relaxing blood vessels and improving blood flow.
Manidipine hydrochloride is used as an antihypertensive agent for managing high blood pressure. Its dihydropyridine calcium channel blocking properties allow it to selectively target vasculature, leading to a reduction in blood pressure.
Used in Antiviral Applications:
Manidipine hydrochloride is used as an inhibitor of the SARS-CoV-2 main protease, 3CLpro, for potential treatment of COVID-19. Its ability to inhibit this protease may help in limiting the replication of the virus.
Manidipine hydrochloride is used as an early entry inhibitor of human cytomegalovirus by inhibiting the Immediate-Early 2 (IE2) protein. This application may help in preventing the virus from entering and infecting host cells, thus limiting the spread of the infection.
References
Kakihana et al. (1988), Antihypertensive effect of CV-4093·2HCl, a new calcium antagonist, in three rat models of hypertension; Jpn. J. Pharmacol., 48 223
McKeage (2004), Manidipine: a review of its use in the management of hypertension; Drugs, 64 1923
Ghahremanpour et al. (2020), Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2; ACS Med. Chem. Lett., 11 2526
Mercorelli et al. (2018), Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early entry inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein; Antiviral Res., 150 130
Check Digit Verification of cas no
The CAS Registry Mumber 89226-75-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,2,2 and 6 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 89226-75:
(7*8)+(6*9)+(5*2)+(4*2)+(3*6)+(2*7)+(1*5)=165
165 % 10 = 5
So 89226-75-5 is a valid CAS Registry Number.
InChI:InChI=1/C35H38N4O6.ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;/h4-16,23,32-33,36H,17-22H2,1-3H3;1H
89226-75-5Relevant articles and documents
Improved manidipine dihydrochloride II crystal form production method
-
Paragraph 0046; 0047, (2018/07/30)
The invention discloses an improved manidipine dihydrochloride II crystal form production method. The method comprises the steps: adding concentrated grease containing manidipine alkali into ethyl alcohol, stirring to befor crystallizedcrystallizing, filtering to obtain filter cake and pulping and washing to obtain the manidipine alkali; then utilizing hydrochloric acid salification to obtain a manidipine dihydrochloride crude product; heating and dissolving the manidipine dihydrochloride crude product by methyl alcohol containing water, performing thermal-insulation filtration, crystallization and filtration, collecting separated-out crystal and drying to obtain the manidipine dihydrochloride II crystal form. The purity of the II crystal form obtained by the production method disclosed bythe invention is larger than 99.8%, and the method has very great guiding significance in researches of the manidipine dihydrochloride crystal form and clinical application of manidipine dihydrochloride.
S-Manidipine hydrochloride crystal form I and preparation method thereof
-
Paragraph 0054; 0055, (2017/04/08)
The invention relates to an S-Manidipine hydrochloride crystal form I and a preparation method thereof. The preparation method includes: dissolving S-Manidipine free alkali into alcohols or alcohol/water, salifying with HCL, and crystallizing to obtain S-Manidipine hydrochloride crystal which is determined as the crystal form I according to X-ray powder diffraction detection. Products of the S-Manidipine hydrochloride crystal form I have excellent temperature and humidity stability, meet quality requirements on residual solvent and moisture and are suitable for preparation process and long-term storage. Pharmaceutical compositions with compounds of the crystal form I serving as active ingredients can be used for treating diseases such as hypertension and the like.
POLYMORPHIC FORMS OF MANIDIPINE
-
, (2011/04/14)
The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.